Tyme Technologies Inc  

(Public, NASDAQ:TYME)   Watch this stock  
Find more results for TYME
+0.03 (0.49%)
Real-time:   2:24PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.96 - 7.00
52 week 2.01 - 9.50
Open 6.22
Vol / Avg. 516,518.00/179,963.00
Mkt cap 552.00M
P/E     -
Div/yield     -
EPS -0.16
Shares 89.32M
Beta -42.35
Inst. own 10%

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -204.43% -199.97%
Return on average equity -294.48% -292.23%
Employees 9 -
CDP Score - -


44 Wall St Fl 12
NEW YORK, NY 10005-2433
United States - Map
+1-646-2051603 (Phone)
+1-845-8183588 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.